Efficacy of glucantime for treatment of cutaneous leishmaniasis in Central Iran

Journal of Infection and Public Health

Volumn 6, Issue 2, 2013, Pages 120-124

  Mohammadzadeh, Mahmoud ^a   Behnaz, Fatemah ^a   Golshan, Zahra ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cutaneous leishmaniasis; Efficacy; Glucantime; Iran

Indexed keywords

ANTIMONY; AZITHROMYCIN; KETOCONAZOLE; MEGLUMINE ANTIMONATE; PAROMOMYCIN;

ABSCESS; ADOLESCENT; ADULT; AGED; ARTICLE; BODY WEIGHT; CELLULITIS; CHILD; CRYOTHERAPY; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TREATMENT FAILURE; ECZEMA; FAINTNESS; FEMALE; HERPES ZOSTER; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INFANT; IRAN; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; SCHOOL CHILD; SKIN LEISHMANIASIS; TREATMENT DURATION; URINE RETENTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIPROTOZOAL AGENTS; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFANT; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAMUSCULAR; IRAN; LEISHMANIASIS, CUTANEOUS; MALE; MEGLUMINE; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875576625     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2012.11.003     Document Type: Article

References (21)

1. Nadim A., Sayedi-Rashti M.A. A brief review of the epidemiology of various types of leishmaniasis in Iran. Acta Medica Iranica 1971, XIV:99-106.
2. Yaghoubi M.R., Hanafi A.A., Javadian E., Jafari R., Mohebali M. A new focus of cutaneous leishmaniasis caused by Leishmania tropica. Saudi Medical Journal 2002, 24:98-101.
3. Soto J., Toledo J., Vega J., Berman J. Short report: efficacy of pentavalent antimony for treatment of Colombian cutaneous leishmaniasis. American Journal of Tropical Medicine and Hygiene 2005, 72(4):421-422.
4. Llanos-cuentas A., Tulliano G., Araujo-castillo R., Miranda-Verastegui C., Santamaria-casterello G., Ramirez L., et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clinical Infectious Diseases 2008, 46:223-231.
5. Palasios R., Elena Osorio L., Fernando GraJales L., Tresa Ochoa M. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to leishmania vianna species. American Journal of Tropical Medicine and Hygiene 2001, 64(3, 4):87-93.
6. Mohebali M., Fotouhi M.A., Hooshmand B.B., Zarei Z., Akhoundi B., Rahnema A., Razaghian A.R., Kabir M.J., Nadim A. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran. Acta Tropica 2007, 103:33-40.
7. Momeni A.Z., Aminjavaheri M. Treatment of non-healing cases of cutaneous leishmaniasis, successful treatment using a combination of meglumine antimoniate plus allopurinol. European Journal of Dermatology 2003, 13(January-February (1)):40-43.
8. Firdous R., Yasunzai M., Ranja K. Efficacy of Glucantime in the treatment of old world cutaneous leishmaniasis. International Journal of Dermatology 2009, 48:758-762.
9. Hadighi R., Boucher P., Khamesipour A., Meamar A.R., Roy G., Ouellette M., Mohebali M. Glucantime-resistant Leishmania tropica isolated from Iranian patients with cutaneous leishmaniasis. Journal of Parasitology Research 2007, 101:1319-1322. 10.1007/s00436-007-0638-0.
10. Rodrigues A.M., Hueb M., Santos T.A., Fontes C. J Factors associated with treatment failure of cutaneous leishmaniasis with meglumine antimoniate. Revista da Sociedade Brasileira de Medicina Tropical 2006, 39(2):139-145. 10.1590/S0037-86822006000200001.
11. Samady J.A., Janniger C.K., Schwartz R.A. Cutaneous and mucocutaneous leishmaniasis. Cutis 1996, 57:13-20.
12. Pourmohammadi B., Motazedian M.H., Handjani F., Hatam G.H.R., Habibi S., Sarkari B. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis. The Southeast Asian Journal of Tropical Medicine and Public Health 2011, 42(May (3)):502-508.
13. Munir A., Janjua S.A., Husain I. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis. Acta Dermatovenerologica Croatica 2008, 16(2):60-64.
14. Teixeira A.C., Gomes PAES.M., Guerra J.O., Prata A., Silva-Vergara M.L. Failure of both azithromycin and antimony to treat cutaneous leishmaniasis in Manaus, AM, Brazil. Revista do Instituto de Medicina Tropical de Sao Paulo 2008, 50(May/June (3)):157-160. 10.1590/S0036-46652008000300005.
15. Croft S.L., Sundar S., Fairlamb A.H. Drug resistance in leishmaniasis. Clinical Microbiology Reviews 2006, 19(January (1)):111-126. 10.1128/CMR.19.1.111-126.2006.
16. Olliaro P.L., Guerin P.J., Gerstl S., Haaskjold A.A., Rottingen J.A., Sundar S. Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infectious Diseases 2005, 5:763-774.
17. Iraji F., Vali A., Asilian A., Shahtalebi M.A., Momeni A. Comparison of intralesionally injected zinc sulfate with meglumine antimoniate in the treatment of acute cutaneous leishmaniasis. Dermatology 2004, 209:46-49.
18. Oliveria-Neto M.P., Mattos M.S. An alternative antimonial schedule to be used in cutaneous leishmaniasis when high doses of antimony are undesirable. Revista da Sociedade Brasileira de Medicina Tropical 2006, 4:323-326.
19. Wortman R.G., Miller S., Oster C., Jackson J., Naomi Aronson A., Randomized Double-blind study of the efficacy of a 10- or 20-day course of sodium stibogluconate for treatment of cutaneous leishmaniasis in United States Military Personnel. Clinical Infectious Diseases 2002, 35:261-267.
20. Mlika B.R., El Aïdli S., Ben Brahim M., Badri T., Chouk S., Ben Jannet S., et al. Adverse events related to systemic treatment using Glucantime for cutaneous leishmaniasis: a report from Tunisia [Article in French]. Medecine Tropicale 2008, 68(October (5)):499-501.
21. Berman J.D. Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clinical Infectious Diseases 1997, 24:684-703.